IsoRay announced another step forward in international adoption of its ground-breaking GliaSite® radiation therapy system, the world's only liquid radiation balloon catheter device used in the treatment of brain cancers. IsoRay shipped its first orders to Germany as mounting inquiries continue to grow Company confidence in the international market. According to IsoRay CEO Dwight Babcock, "The medical community is clearly becoming aware of the innovative alternative that GliaSite presents as an important advance over previous brain cancer treatments. We are seeing a growth in inquiries from Germany, Italy, Austria, Switzerland, and the U.K.."
- international adoption